Thema: Studie: EMD 121974 Therapie maligner Gliom-Rezidive

Treatment Name:
NABTT 9911
A Phase I/II Trial of EMD 121974 for Treatment of Patients with Recurrent Malignant Gliomas

Phase:
Phase 1/2 EMD for recurrent malignant gliomas

Age Group:
Adults Only

Min Karnofsky Score: 60:
Requires occasional assistance but is able to care for most of own needs

Conditions:
Prior Surgery is Allowed
Prior Radiation is Allowed
Prior Chemotherapy is Allowed
Patients may have received two prior chemotherapies. Patients must be at least 90 days from completing radiation therapy. Patients must have recurrent malignant glioma Patients with previously low grade glioma who progresed after radiotherapy plus or minus chemotherapy an d are biopsied and found to have a high grade glioma are eligible. Patients must have adequate bone marrow, ranal and liver function. Patients must not be pregnant or nursing. Patients must follow birth control measures. Patients must be able to tolerate MRI`s.

Tumor Types:
Anaplastic Astrocytoma, Glioblastoma Multiforme, Oligodendroglioma High Grade

Comments:
EMD is an antineogesis agent. This is administered IV via a central line, twice weekly...Monday/Thursday or Tuesday/Friday. A cycle is 4 weeks.


Contact:
Jean E. Kracher
Executive Director
Mass. General Hospital - Brain Tumor Center
Suite 315, Cox Building
Boston, MA 02114 USA
Phone: (617)724-8870
Fax: (617)724-8769
Website: brain.mgh.harvard.edu/